Anzeige
Mehr »
Donnerstag, 30.04.2026 - Börsentäglich über 12.000 News
250 Tage bis zum Pentagon-Magnetverbot: Wie ein 46-Mio.-CAD-Small-Cap profitieren könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A422GY | ISIN: US72941H8060 | Ticker-Symbol: XMP1
Frankfurt
29.04.26 | 08:02
4,985 Euro
-0,70 % -0,035
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiPlus Therapeutics Inc.: Plus Therapeutics Secures Blue Shield of California Coverage for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer3
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
23.04.Plus Therapeutics Initiates Manufacturing Activities, Tech Transfer With SpectronRx10
23.04.Plus Therapeutics Inc.: Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ292HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
► Artikel lesen
23.04.XFRA XMP1: WIEDERAUFNAHME/RESUMPTION178FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
22.04.Plus Therapeutics Inc.: Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)3
21.04.Plus Therapeutics regains compliance with Nasdaq14
21.04.Plus Therapeutics Inc.: Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement265HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
► Artikel lesen
21.04.PLUS THERAPEUTICS, INC. - 8-K, Current Report1
15.04.Plus Therapeutics appoints Randy Goodman to lead market access4
15.04.Plus Therapeutics beruft Randy Goodman zum Leiter für Marktzugang und Gesundheitsökonomie6
15.04.Plus Therapeutics Inc.: Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution332HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
► Artikel lesen
10.04.Why Is Plus Therapeutics Stock Gaining Friday?10
09.04.Plus Therapeutics names Eric Daniels as chief development officer3
09.04.Plus Therapeutics Inc.: Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline154HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
► Artikel lesen
08.04.Plus Therapeutics-Aktie legt nach FDA-Zuerkennung des Orphan-Drug-Status zu3
08.04.FDA grants orphan drug status to Plus Therapeutics' REYOBIQ1
08.04.Plus Therapeutics Inc.: Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ in Pediatric Malignant Gliomas208HOUSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform...
► Artikel lesen
07.04.Plus Therapeutics Inc.: Plus Therapeutics Receives AMA PLA Code for CNSide CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption488HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals...
► Artikel lesen
02.04.PLUS THERAPEUTICS, INC. - 8-K, Current Report1
02.04.Plus Therapeutics Inc.: Plus Therapeutics Secures Highmark Coverage for CNSide CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives291HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today announces a new payer coverage...
► Artikel lesen
Weiter >>
84 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1